Sarepta Therapeutics Inc at Cowen Health Care Conference (Virtual) Transcript
Good afternoon, everyone. Welcome to the home stretch Day 3 of Cowen's 2022 Healthcare Conference. I'm senior analyst Ritu Baral, covering analyst on Sarepta. And thanks for joining the Sarepta fireside chat. With us today is CEO, Doug Ingram. Hi, Doug, thanks for joining us. So let's get started.
Questions & Answers
Literally, every single Sarepta question that I've had since your earnings call has been on your guidance, long-term guidance that you gave unexpectedly, unexpectedly on the call last week, where you promised potential breakeven by 2024, $4 billion in revenue guidance 2025 and potentially $10 billion by the end of the decade. You and I spoke about this briefly, but why now? Did the plan come together internally? Do you get more clarity from FDA on something? Is this the start of corporate strategy, et cetera?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |